10 papers2 findings
Secukinumab
downin human cells1
Secukinumab decreases IL-17 in human cells.
“revealed significant upregulation of pathogenic factors such as IL-8 and IL-17, which were attenuated by SB225002 (anti-CXCR2) and secukinumab (anti-IL-17A).”
Cellsin CEnCs after chronic UV-A and 4-OHE2 exposurecorneal endothelium
Cell death & disease2 Feb 2026
IFNAR1
downin mice1
IFNAR1 decreases IL-17 in mice.
“mice lacking the IFN-α receptor maintain Foxo1 expression and exhibit reduced IL-17 production”
Animalsin mice lacking the IFN-alpha receptor
Aging Reshapes γ/δ T-Cell Immunity Through a Type I Interferon-Foxo1 Axis
Aging cell21 Jan 2026
The culture platform maintained native tissue architecture for four weeks, revealing treatment effects on aged donor tissue that emerged only after prolonged exposure.The culture platform maintained native tissue architecture for four weeks, revealing treatment effects on aged donor tissue that emerged only after prolonged exposure.